Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.

O'Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, Eckburg PB, Manley A, Steenbergen JN, Tzanis E, McGovern PC, Loh E; OASIS-2 Investigators.

Lancet Infect Dis. 2019 Aug 29. pii: S1473-3099(19)30275-0. doi: 10.1016/S1473-3099(19)30275-0. [Epub ahead of print]

PMID:
31474458
2.

Omadacycline for Bacterial Infections. Reply.

Garrity-Ryan L, Loh E.

N Engl J Med. 2019 May 23;380(21):2073-2074. doi: 10.1056/NEJMc1903821. No abstract available.

PMID:
31116928
3.

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study.

Overcash JS, Bhiwandi P, Garrity-Ryan L, Steenbergen J, Bai S, Chitra S, Manley A, Tzanis E.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02083-18. doi: 10.1128/AAC.02083-18. Print 2019 May.

4.

Omadacycline for Community-Acquired Bacterial Pneumonia.

Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, Kirsch C, Das AF, Garrity-Ryan L, Steenbergen JN, Manley A, Eckburg PB, Tzanis E, McGovern PC, Loh E.

N Engl J Med. 2019 Feb 7;380(6):517-527. doi: 10.1056/NEJMoa1800201.

PMID:
30726692
5.

Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.

O'Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, Garrity-Ryan L, Das AF, Tzanis E, Eckburg PB, Manley A, Villano SA, Steenbergen JN, Loh E.

N Engl J Med. 2019 Feb 7;380(6):528-538. doi: 10.1056/NEJMoa1800170.

PMID:
30726689
6.

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens.

Bundrant LA, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, Villano S.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01487-17. doi: 10.1128/AAC.01487-17. Print 2018 Feb.

7.

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.

Berg JK, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, Villano S.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e02057-17. doi: 10.1128/AAC.02057-17. Print 2018 Feb.

8.

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Gotfried MH, Horn K, Garrity-Ryan L, Villano S, Tzanis E, Chitra S, Manley A, Tanaka SK, Rodvold KA.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01135-17. doi: 10.1128/AAC.01135-17. Print 2017 Sep.

9.

In vitro and in vivo antimalarial efficacies of optimized tetracyclines.

Draper MP, Bhatia B, Assefa H, Honeyman L, Garrity-Ryan LK, Verma AK, Gut J, Larson K, Donatelli J, Macone A, Klausner K, Leahy RG, Odinecs A, Ohemeng K, Rosenthal PJ, Nelson ML.

Antimicrob Agents Chemother. 2013 Jul;57(7):3131-6. doi: 10.1128/AAC.00451-13. Epub 2013 Apr 29.

10.

Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model.

Garrity-Ryan LK, Kim OK, Balada-Llasat JM, Bartlett VJ, Verma AK, Fisher ML, Castillo C, Songsungthong W, Tanaka SK, Levy SB, Mecsas J, Alekshun MN.

Infect Immun. 2010 Nov;78(11):4683-90. doi: 10.1128/IAI.01305-09. Epub 2010 Sep 7.

11.

N-Hydroxybenzimidazole inhibitors of ExsA MAR transcription factor in Pseudomonas aeruginosa: In vitro anti-virulence activity and metabolic stability.

Grier MC, Garrity-Ryan LK, Bartlett VJ, Klausner KA, Donovan PJ, Dudley C, Alekshun MN, Tanaka SK, Draper MP, Levy SB, Kim OK.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3380-3. doi: 10.1016/j.bmcl.2010.04.014. Epub 2010 Apr 11.

PMID:
20434913
12.

N-hydroxybenzimidazole inhibitors of the transcription factor LcrF in Yersinia: novel antivirulence agents.

Kim OK, Garrity-Ryan LK, Bartlett VJ, Grier MC, Verma AK, Medjanis G, Donatelli JE, Macone AB, Tanaka SK, Levy SB, Alekshun MN.

J Med Chem. 2009 Sep 24;52(18):5626-34. doi: 10.1021/jm9006577.

13.

The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence.

Balachandran P, Dragone L, Garrity-Ryan L, Lemus A, Weiss A, Engel J.

J Clin Invest. 2007 Feb;117(2):419-27. Epub 2007 Jan 18.

14.

MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis.

Casaz P, Garrity-Ryan LK, McKenney D, Jackson C, Levy SB, Tanaka SK, Alekshun MN.

Microbiology. 2006 Dec;152(Pt 12):3643-50.

PMID:
17159217
15.

The ADP ribosyltransferase domain of Pseudomonas aeruginosa ExoT contributes to its biological activities.

Garrity-Ryan L, Shafikhani S, Balachandran P, Nguyen L, Oza J, Jakobsen T, Sargent J, Fang X, Cordwell S, Matthay MA, Engel JN.

Infect Immun. 2004 Jan;72(1):546-58.

16.

Pseudomonas aeruginosa ExoT inhibits in vitro lung epithelial wound repair.

Geiser TK, Kazmierczak BI, Garrity-Ryan LK, Matthay MA, Engel JN.

Cell Microbiol. 2001 Apr;3(4):223-36.

PMID:
11298646
17.

Supplemental Content

Loading ...
Support Center